Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.

You may also be interested in...

Schering Noxafil Phase III

Schering-Plough's triazole antifungal Noxafil (posaconazole oral suspension) shows significantly better results than standard antifungals in a study presented Dec. 8 at the American Society of Hematology meeting. Overall success rate was 42% in patients receiving Noxafil 800 mg/day for up to one year, vs. 26% for standard therapy (p=0.006). Noxafil is one of three launches Schering is anticipating by 2007; the firm also expects to introduce the oncologic Sarasar (lonafarnib) and a fixed combination of Zetia and Zocor, which is pending at FDA with a July user fee goal...

Zetia/Zocor Combo User Fee In July 2004; Genentech Sees Avastin On Time

The user fee deadline for Merck/Schering-Plough’s Zetia/Zocor combination product for cholesterol reduction is July 24, 2004.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts